Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in
treating patients who have advanced melanoma or other metastatic or unresectable cancer.
Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the
tumor. Combining imatinib mesylate with bevacizumab may kill more tumor cells